1AD 3.85% 2.5¢ adalta limited

I never said the conference wasn't worthwhile - just that 1AD...

  1. 451 Posts.
    lightbulb Created with Sketch. 1
    I never said the conference wasn't worthwhile - just that 1AD shouldn't be attending. It is a pointless exercise for them to continually pedal the same pre-clinical story until they have some hard data. The story is 'known' - it just isn't being 'bought' atm. And it annoys we that they are doing so so soon after a somewhat botched capital raising.
    On reflection I'll stick with naive indignation.
 
watchlist Created with Sketch. Add 1AD (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.